Page 77 - Drug Class Review
P. 77
Drug Effectiveness Review Project
Withdrawals due to adverse events: A meta-analysis of withdrawals before the end of treatment showed
no significant differences between the 5 mg/d group and the placebo group at 12 and 24 weeks; there were
significant differences for the 10 mg/d group in favor of placebo at 12, but not at 24 and 52 weeks (29/184
Anorexia, diarrhea, dizziness, fatigue, insomnia, muscle cramps, nausea, vomiting, tremor, vertigo, and
weight loss were statistically significantly more common in the DON than in the placebo group
DON, 13/178 placebo) (OR 2.31; 95% CI: 1.21 – 4.40, P = 0.01)
Group Trials were selected from Specialized Register of the Cochrane Dementia and Cognitive Improvement Yes Good Page 69 of 205
Final Report Update 1 Authors: Birks et al. Year: 2004 ADVERSE EVENTS: COMPREHENSIVE LITERATURE SEARCH STRATEGY: STANDARD METHOD OF APPRAISAL OF STUDIES: QUALITY RATING: Alzheimer's Drugs
